Kolibri's project aims to address the weaknesses in respiratory care in Germany, as 10% of the population suffers from respiratory diseases, including asthma and COPD.
The project targets challenges such as uncontrolled particle deposition, high risks in clinical development, patient acceptance and adherence. OECHSLER & PULMOTREE aim to develop innovative solutions to optimize drug delivery, mitigate risks, and enhance patient experiences. This project is a testimony to OECHSLER’s pioneering spirit and paves the way for a brighter future in respiratory health through advancements in drug delivery technology.
OECHSLER and PULMOTREE came together for a compelling reason. PULMOTREE, a start-up company founded by Ulf Kreuger and specializing in respiratory disease care, recognized the need to address gaps in the current market and meet the specific requirements of patients, physicians, and pharmaceutical companies. With OECHSLER's 70 years of expertise in injection molding, the company became an interesting and experienced partner that could go beyond a traditional customer-supplier relationship. The collaboration between OECHSLER and PULMOTREE has brought the Kolibri mash nebulizer to life, a product that was developed as a prototype and through their joint efforts will reach mass production.